Year: 2023
Type: editorial
Abstract: Editorial on the Research Topic Immunogenicity and toxicity of AAV gene therapyRecombinant adeno-associated virus (AAV) is a promising delivery vehicle for in vivo gene therapy and has been widely tested in preclinical and clinical studies.However, despite the vast promise they hold for gene therapy, debilitating immune responses have been reported against the AAV capsid itself and/or to the transgene product.As a result of high vector doses, serious adverse effects like complement activation and liver toxicity have been observed, even leading to fatality of subjects in certain clinical trials.Although many of these adverse events can be managed with immunosuppressants, this is not true for all trial participants.To gain a better understanding of factors that may influence AAV immunity and durability, Shen et al. conducted a meta-analysis of 255 AAV clinical trials over the past 25 years.The usage of immunosuppressants and antibody screening assays highly depended on the indications, with relatively lower frequency among trials for treating retinal and central nervous system (CNS) diseases.The rates of treatment emergent serious adverse events (TESAEs) also varied by indication, routes of administration, serotype, and dosage, with CNS diseases having the highest risk.Other interesting findings of their analysis include a broad range of AAV neutralizing antibody titer cutoffs between trials and that the vector production platform had no impact on gene therapy durability or frequency of adverse events.Recently, complement-mediated AEs have emerged as contributing to immunemediated toxicities, specifically in high-dose systemic delivery of AAV vectors.Because animal models have not shown a direct role of complement in AAV mediated toxicities, detailed mechanistic studies are lacking.To address this knowledge gap, Smith et al. conducted studies in human PBMCs obtained from multiple donors and found that high AAV neutralizing antibody titers >1:100 enhanced the uptake of AAV viral particles (empty or full) in several immune cells including neutrophils, monocyte-related dendritic cells, and monocytes leading to increased production of pro-inflammatory cytokines/ chemokines and complement activation.Uptake and immune cell activation by AAV vectors were significantly reduced with a C3 inhibitor, APL-9.
Source: Frontiers in Immunology
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,295
OpenAlex ID: W4381892477
